Probiotic trial to help irinotecan work better in metastatic colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven metastatic colon cancer
- Your cancer plan is to use irinotecan as a second or later treatment (every 2 weeks) at a set starting dose
- You are well enough for study treatment (performance status 0–1)
- Your blood and liver/kidney tests are within trial limits (your team will confirm)
- You do NOT have a specific genetic marker called UGTA1A* (your team can test this)
- You can take oral supplements and are not currently taking antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
This trial tests whether adding a probiotic (a beneficial bacteria) to a standard chemo-immunotherapy combination can improve outcomes for people with metastatic colorectal cancer that hasn't responded to earlier treatments.
This study tests whether taking a probiotic supplement during chemotherapy can help people with stage III colon cancer. It aims to see if it improves treatment outcomes or reduces side effects.
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
This study looks at the bacteria in your mouth, gut, and tumors to see if they affect how well first-line immunotherapy works. It is for people with advanced stomach, colorectal, breast, cervical, or head-and-neck cancer.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Hear when a new Stage IV Colon Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.